StockNow
Calendar
Log in
U.S. Markets

Eli Lilly (LLY) announces Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

ORIGINAL · NewsquawkEli Lilly (LLY) announces Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
StockNow breaking-news AI analysis

Lilly announced improved and durable 52-week TOGETHER-PsA results for Taltz plus Zepbound; a Nov. 5 report said it would also showcase both drugs at ACR Convergence 2026.

1 stocks
LLYEli Lilly & Co.$1,430.58Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Russia's Top Ukraine Negotiator Medinsky says it seems like we are closer to peace, but now a lot depends on all participants in the process

Fed

Internal debate at the Fed over the departure date for Williams, Bloomberg reports citing sources

Geopolitics

Iran's Rezaei says they will target US military bases within Europe if US craft depart from there to strike Iran. Elsewhere, discussed with Russian President Putin the importance of the North Sea corridor, and the possible transfer of Russian gas to Iran